Schizophrenia

© Getty Images

Sosei Heptares doses first patient in schizophrenia drug trial

By Isabel Cameron

Sosei Heptares has dosed the first subject in a phase 1 trial evaluating HTL’149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.